Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 84

1.

Establishing a Core Outcome Measure for Life Participation: A Standardized Outcomes in Nephrology-kidney Transplantation Consensus Workshop Report.

Ju A, Josephson MA, Butt Z, Jowsey-Gregoire S, Tan J, Taylor Q, Fowler K, Dobbels F, Caskey F, Jha V, Locke J, Knoll G, Ahn C, Hanson CS, Sautenet B, Manera K, Craig JC, Howell M, Rutherford C, Tong A, Harden P, Hawley C, Holdaas H, Israni A, Jesse M, Kane B, Kanellis J, Kiberd B, Kim J, Larsen C, Leichtman A, Lentine K, Malone A, Mannon R, Oberbauer R, Patzer R, Peipert JD, Phan HA, Poggio E, Reed R, Scandling J, Tang I, Watson C, Contrares D, Contreras P, Cross D, Juodvalkis E, Koide D, Koide J, Kozarewicz A, Kozarewicz L, Kozarewicz R, Koritala A, Lisiecki E, Lipuma C, Lyman M, Mueller R, Mueller G, Noble L, Nolan N, Nolan S, Thomas J, Urbancyzk L, Zerante J, Zerante S; SONG-Tx Life Participation Workshop Investigators; Health professionals (*includes 2 patients from the SONG-Tx Graft Health Expert Working Group); Patients and family members.

Transplantation. 2019 Jun;103(6):1199-1205. doi: 10.1097/TP.0000000000002476.

PMID:
30300284
2.

A new approach to kidney wait-list management in the kidney allocation system era: Pilot implementation and evaluation.

Cheng XS, Busque S, Lee J, Discipulo K, Hartley C, Tulu Z, Scandling JD, Tan JC.

Clin Transplant. 2018 Nov;32(11):e13406. doi: 10.1111/ctr.13406. Epub 2018 Oct 15.

PMID:
30218580
3.

Macrochimerism and clinical transplant tolerance.

Scandling JD, Busque S, Lowsky R, Shizuru J, Shori A, Engleman E, Jensen K, Strober S.

Hum Immunol. 2018 May;79(5):266-271. doi: 10.1016/j.humimm.2018.01.002. Epub 2018 Jan 9. Review.

4.

Developing Consensus-Based Priority Outcome Domains for Trials in Kidney Transplantation: A Multinational Delphi Survey With Patients, Caregivers, and Health Professionals.

Sautenet B, Tong A, Manera KE, Chapman JR, Warrens AN, Rosenbloom D, Wong G, Gill J, Budde K, Rostaing L, Marson L, Josephson MA, Reese PP, Pruett TL, Hanson CS, O'Donoghue D, Tam-Tham H, Halimi JM, Shen JI, Kanellis J, Scandling JD, Howard K, Howell M, Cross N, Evangelidis N, Masson P, Oberbauer R, Fung S, Jesudason S, Knight S, Mandayam S, McDonald SP, Chadban S, Rajan T, Craig JC.

Transplantation. 2017 Aug;101(8):1875-1886. doi: 10.1097/TP.0000000000001776.

5.

All's well following living kidney donation?

Scandling JD.

Transpl Int. 2017 Oct;30(10):972-974. doi: 10.1111/tri.13000. No abstract available.

6.

Long-term Follow-up of Kidney Transplant Recipients in the Spare-the-Nephron-Trial.

Weir MR, Pearson TC, Patel A, Peddi VR, Kalil R, Scandling J, Chan L, Baliga P, Melton L, Mulgaonkar S, Waid T, Schaefer H, Youssef N, Anandagoda L, McCollum D, Lawson S, Gordon R.

Transplantation. 2017 Jan;101(1):157-165. doi: 10.1097/TP.0000000000001098.

PMID:
26950714
7.

A Cost Analysis of Tolerance Induction for Two-Haplotype Match Kidney Transplant Recipients.

Erickson KF, Winkelmayer WC, Busque S, Lowsky R, Scandling JD, Strober S.

Am J Transplant. 2016 Jan;16(1):371-3. doi: 10.1111/ajt.13530. Epub 2015 Nov 9. No abstract available.

8.

HCV infection is associated with lower survival in simultaneous liver kidney transplant recipients in the United States.

Perumpail RB, Wong RJ, Scandling JD, Ha le D, Todo T, Bonham CA, Saab S, Younossi ZM, Ahmed A.

Clin Transplant. 2015 Oct;29(10):920-6. doi: 10.1111/ctr.12598. Epub 2015 Aug 29.

PMID:
26205329
9.

Chimerism, graft survival, and withdrawal of immunosuppressive drugs in HLA matched and mismatched patients after living donor kidney and hematopoietic cell transplantation.

Scandling JD, Busque S, Shizuru JA, Lowsky R, Hoppe R, Dejbakhsh-Jones S, Jensen K, Shori A, Strober JA, Lavori P, Turnbull BB, Engleman EG, Strober S.

Am J Transplant. 2015 Mar;15(3):695-704. doi: 10.1111/ajt.13091.

10.

A Three-Gene Assay for Monitoring Immune Quiescence in Kidney Transplantation.

Roedder S, Li L, Alonso MN, Hsieh SC, Vu MT, Dai H, Sigdel TK, Bostock I, Macedo C, Metes D, Zeevi A, Shapiro R, Salvatierra O, Scandling J, Alberu J, Engleman E, Sarwal MM.

J Am Soc Nephrol. 2015 Aug;26(8):2042-53. doi: 10.1681/ASN.2013111239. Epub 2014 Nov 26.

11.

Correlates and outcomes of warfarin initiation in kidney transplant recipients newly diagnosed with atrial fibrillation.

Lenihan CR, Montez-Rath ME, Shen JI, Scandling JD, Turakhia MP, Chang TI, Winkelmayer WC.

Nephrol Dial Transplant. 2015 Feb;30(2):321-9. doi: 10.1093/ndt/gfu323. Epub 2014 Oct 21.

12.

Outcomes after kidney transplantation of patients previously diagnosed with atrial fibrillation.

Lenihan CR, Montez-Rath ME, Scandling JD, Turakhia MP, Winkelmayer WC.

Am J Transplant. 2013 Jun;13(6):1566-75. doi: 10.1111/ajt.12197.

13.

Tolerance and withdrawal of immunosuppressive drugs in patients given kidney and hematopoietic cell transplants.

Scandling JD, Busque S, Dejbakhsh-Jones S, Benike C, Sarwal M, Millan MT, Shizuru JA, Lowsky R, Engleman EG, Strober S.

Am J Transplant. 2012 May;12(5):1133-45. doi: 10.1111/j.1600-6143.2012.03992.x. Epub 2012 Mar 8.

14.

Induced immune tolerance for kidney transplantation.

Scandling JD, Busque S, Shizuru JA, Engleman EG, Strober S.

N Engl J Med. 2011 Oct 6;365(14):1359-60. doi: 10.1056/NEJMc1107841. No abstract available.

15.

Living donor evaluation and exclusion: the Stanford experience.

Lapasia JB, Kong SY, Busque S, Scandling JD, Chertow GM, Tan JC.

Clin Transplant. 2011 Sep-Oct;25(5):697-704. doi: 10.1111/j.1399-0012.2010.01336.x. Epub 2010 Nov 2.

16.

United network for organ sharing (UNOS) organ allocation policy and kidney utilization.

Scandling JD, Norman DJ.

Am J Kidney Dis. 2010 Jul;56(1):7-9. doi: 10.1053/j.ajkd.2010.04.004. No abstract available.

PMID:
20620682
17.

Tolerance and chimerism after renal and hematopoietic-cell transplantation.

Scandling JD, Busque S, Dejbakhsh-Jones S, Benike C, Millan MT, Shizuru JA, Hoppe RT, Lowsky R, Engleman EG, Strober S.

N Engl J Med. 2008 Jan 24;358(4):362-8. doi: 10.1056/NEJMoa074191.

18.

Rituximab failed to improve nephrotic syndrome in renal transplant patients with recurrent focal segmental glomerulosclerosis.

Yabu JM, Ho B, Scandling JD, Vincenti F.

Am J Transplant. 2008 Jan;8(1):222-7. Epub 2007 Nov 2.

19.

Acquired cystic kidney disease and renal cell cancer after transplantation: time to rethink screening?

Scandling JD.

Clin J Am Soc Nephrol. 2007 Jul;2(4):621-2. Epub 2007 Jun 6. Review. No abstract available.

20.

High rates of coronary artery stenosis detected by angiography in diabetic renal transplant candidates.

Scandling JD.

Nat Clin Pract Nephrol. 2007 Apr;3(4):194-5. Epub 2007 Feb 6. No abstract available.

PMID:
17290238
21.

Validation of a screening protocol for identifying low-risk candidates with type 1 diabetes mellitus for kidney with or without pancreas transplantation.

Ma IW, Valantine HA, Shibata A, Waskerwitz J, Dafoe DC, Alfrey EJ, Tan JC, Millan M, Busque S, Scandling JD.

Clin Transplant. 2006 Mar-Apr;20(2):139-46.

PMID:
16640517
22.

The role of pre-emptive re-transplant in graft and recipient outcome.

Goldfarb-Rumyantzev AS, Hurdle JF, Baird BC, Stoddard G, Wang Z, Scandling JD, Barenbaum LL, Cheung AK.

Nephrol Dial Transplant. 2006 May;21(5):1355-64. Epub 2006 Feb 13.

PMID:
16476722
23.

Kidney transplant candidate evaluation.

Scandling JD.

Semin Dial. 2005 Nov-Dec;18(6):487-94. Review.

PMID:
16398711
24.

The role of pretransplantation renal replacement therapy modality in kidney allograft and recipient survival.

Goldfarb-Rumyantzev AS, Hurdle JF, Scandling JD, Baird BC, Cheung AK.

Am J Kidney Dis. 2005 Sep;46(3):537-49.

PMID:
16129217
25.

Renal juxtaglomerular apparatus hyperplasia.

Troxell ML, Scandling JD, Sibley RK.

Nephrol Dial Transplant. 2005 Oct;20(10):2282-3. Epub 2005 Jun 7. No abstract available.

PMID:
15941848
26.

Duration of end-stage renal disease and kidney transplant outcome.

Goldfarb-Rumyantzev A, Hurdle JF, Scandling J, Wang Z, Baird B, Barenbaum L, Cheung AK.

Nephrol Dial Transplant. 2005 Jan;20(1):167-75. Epub 2004 Nov 16.

PMID:
15546892
27.

Dual-kidney transplantation with organs from expanded criteria donors: a long-term follow-up.

Tan JC, Alfrey EJ, Dafoe DC, Millan MT, Scandling JD.

Transplantation. 2004 Sep 15;78(5):692-6.

PMID:
15371670
28.

Prospective, randomized trial of the effect of antibody induction in simultaneous pancreas and kidney transplantation: three-year results.

Burke GW 3rd, Kaufman DB, Millis JM, Gaber AO, Johnson CP, Sutherland DE, Punch JD, Kahan BD, Schweitzer E, Langnas A, Perkins J, Scandling J, Concepcion W, Stegall MD, Schulak JA, Gores PF, Benedetti E, Danovitch G, Henning AK, Bartucci MR, Smith S, Fitzsimmons WE.

Transplantation. 2004 Apr 27;77(8):1269-75.

PMID:
15114097
29.

Approaches to transplantation tolerance in humans.

Strober S, Lowsky RJ, Shizuru JA, Scandling JD, Millan MT.

Transplantation. 2004 Mar 27;77(6):932-6. Review.

PMID:
15077041
30.

Prediction of 3-yr cadaveric graft survival based on pre-transplant variables in a large national dataset.

Goldfarb-Rumyantzev AS, Scandling JD, Pappas L, Smout RJ, Horn S.

Clin Transplant. 2003 Dec;17(6):485-97.

PMID:
14756263
31.

A randomized, placebo-controlled trial of IGF-1 for delayed graft function: a human model to study postischemic ARF.

Hladunewich MA, Corrigan G, Derby GC, Ramaswamy D, Kambham N, Scandling JD, Myers BD.

Kidney Int. 2003 Aug;64(2):593-602.

32.

Randomized trial of tacrolimus + mycophenolate mofetil or azathioprine versus cyclosporine + mycophenolate mofetil after cadaveric kidney transplantation: results at three years.

Gonwa T, Johnson C, Ahsan N, Alfrey EJ, Halloran P, Stegall M, Hardy M, Metzger R, Shield C 3rd, Rocher L, Scandling J, Sorensen J, Mulloy L, Light J, Corwin C, Danovitch G, Wachs M, VanVeldhuisen P, Leonhardt M, Fitzsimmons WE.

Transplantation. 2003 Jun 27;75(12):2048-53.

PMID:
12829910
33.

Increased expression of cytotoxic effector molecules: different interpretations for steroid-based and steroid-free immunosuppression.

Satterwhite T, Chua MS, Hsieh SC, Chang S, Scandling J, Salvatierra O, Sarwal MM.

Pediatr Transplant. 2003 Feb;7(1):53-8.

PMID:
12581329
34.

Quantification of immunosuppression by flow cytometry in stable renal transplant recipients.

Stalder M, Bîrsan T, Holm B, Haririfar M, Scandling J, Morris RE.

Ther Drug Monit. 2003 Feb;25(1):22-7.

PMID:
12548140
35.

Conversion of stable renal allograft recipients to a bioequivalent cyclosporine formulation.

Roza A, Tomlanovich S, Merion R, Pollak R, Wright F, Rajagopalan P, Pruett T, Scandling J, Ryan J, Awni W, Schweitzer S, Greco R, Lam W, Nabulsi A, Hoffman R.

Transplantation. 2002 Oct 15;74(7):1013-7.

PMID:
12394847
36.

Late post-transplant anemia in adult renal transplant recipients. An under-recognized problem?

Yorgin PD, Scandling JD, Belson A, Sanchez J, Alexander SR, Andreoni KA.

Am J Transplant. 2002 May;2(5):429-35.

37.

Mixed chimerism and immunosuppressive drug withdrawal after HLA-mismatched kidney and hematopoietic progenitor transplantation.

Millan MT, Shizuru JA, Hoffmann P, Dejbakhsh-Jones S, Scandling JD, Grumet FC, Tan JC, Salvatierra O, Hoppe RT, Strober S.

Transplantation. 2002 May 15;73(9):1386-91.

PMID:
12023614
38.

Maintenance and recovery stages of postischemic acute renal failure in humans.

Ramaswamy D, Corrigan G, Polhemus C, Boothroyd D, Scandling J, Sommer FG, Alfrey E, Higgins J, Deen WM, Olshen R, Myers BD.

Am J Physiol Renal Physiol. 2002 Feb;282(2):F271-80.

39.

Randomized trial of tacrolimus plus mycophenolate mofetil or azathioprine versus cyclosporine oral solution (modified) plus mycophenolate mofetil after cadaveric kidney transplantation: results at 2 years.

Ahsan N, Johnson C, Gonwa T, Halloran P, Stegall M, Hardy M, Metzger R, Shield C 3rd, Rocher L, Scandling J, Sorensen J, Mulloy L, Light J, Corwin C, Danovitch G, Wachs M, VanVeldhuisen P, Salm K, Tolzman D, Fitzsimmons WE.

Transplantation. 2001 Jul 27;72(2):245-50.

PMID:
11477347
40.

Revisiting the use of hepatitis B core antibody-positive donor kidneys.

Krieger NR, Vial CM, Millan MT, Imperial J, Dafoe DC, Scandling JD.

Transplant Proc. 2001 Feb-Mar;33(1-2):1535-6. No abstract available.

PMID:
11267412
41.

Randomized trial of tacrolimus (Prograf) in combination with azathioprine or mycophenolate mofetil versus cyclosporine (Neoral) with mycophenolate mofetil after cadaveric kidney transplantation.

Johnson C, Ahsan N, Gonwa T, Halloran P, Stegall M, Hardy M, Metzger R, Shield C 3rd, Rocher L, Scandling J, Sorensen J, Mulloy L, Light J, Corwin C, Danovitch G, Wachs M, van Veldhuisen P, Salm K, Tolzman D, Fitzsimmons WE.

Transplantation. 2000 Mar 15;69(5):834-41.

PMID:
10755536
42.

Recommendations for the outpatient surveillance of renal transplant recipients. American Society of Transplantation.

Kasiske BL, Vazquez MA, Harmon WE, Brown RS, Danovitch GM, Gaston RS, Roth D, Scandling JD, Singer GG.

J Am Soc Nephrol. 2000 Oct;11 Suppl 15:S1-86.

43.

PAH extraction and estimation of plasma flow in human postischemic acute renal failure.

Corrigan G, Ramaswamy D, Kwon O, Sommer FG, Alfrey EJ, Dafoe DC, Olshen RA, Scandling JD, Myers BD.

Am J Physiol. 1999 Aug;277(2):F312-8. doi: 10.1152/ajprenal.1999.277.2.F312.

PMID:
10444587
44.

Dual kidney transplantation: older donors for older recipients.

Lee CM, Carter JT, Weinstein RJ, Pease HM, Scandling JD, Pavalakis M, Dafoe DC, Alfrey EJ.

J Am Coll Surg. 1999 Jul;189(1):82-91; discussion 91-2.

PMID:
10401744
45.

Power Doppler imaging of acute renal transplant rejection.

Sidhu MK, Gambhir S, Jeffrey RB Jr, Sommer FG, Li KC, Krieger NR, Alfrey EJ, Scandling JD.

J Clin Ultrasound. 1999 May;27(4):171-5.

PMID:
10323186
46.

Sodium reabsorption and distribution of Na+/K+-ATPase during postischemic injury to the renal allograft.

Kwon O, Corrigan G, Myers BD, Sibley R, Scandling JD, Dafoe D, Alfrey E, Nelson WJ.

Kidney Int. 1999 Mar;55(3):963-75.

47.

Plasma glutathione peroxidase and its relationship to renal proximal tubule function.

Whitin JC, Tham DM, Bhamre S, Ornt DB, Scandling JD, Tune BM, Salvatierra O, Avissar N, Cohen HJ.

Mol Genet Metab. 1998 Nov;65(3):238-45.

PMID:
9851889
48.
49.

What is the optimal approach for the end-stage diabetic nephropathy patient considering simultaneous pancreas-kidney transplantation?

Dafoe DC, Scandling JD, Waskerwitz JA, Beinin ML.

Adv Ren Replace Ther. 1998 Jul;5(3):232-40.

PMID:
9686634
50.

Low-dose OKT3 treatment for rejection/induction in kidney and kidney-pancreas transplantation.

Desai DM, Scandling JD, Knoppel C, Dafoe DC, Alfrey EJ.

Transplant Proc. 1998 Jun;30(4):1552-4. No abstract available.

PMID:
9636630

Supplemental Content

Loading ...
Support Center